Literature DB >> 23809991

Percutaneous flexor tenotomy for preventing and treating toe ulcers in people with diabetes mellitus.

Anne Rasmussen1, Ulla Bjerre-Christensen, Thomas Peter Almdal, Per Holstein.   

Abstract

INTRODUCTION: The purpose was to examine the effectiveness of flexor tenotomy in a modified technique to prevent and heal neuropathic and neuroischaemic pressure ulcers on the tip of the toe in claw- or hammer-toe deformities in people with diabetes. PATIENTS AND METHODS: A consequetive 4 years series of 38 patients was retrospectively studied. Percutaneous tenotomy on the superficial and deep flexor tendons was performed in 65 toes through a small transverse plantar stab incision just proximal to the web level. There were 16 (42%) patients with 27 ulcerated toes and 22 (58%) patients with 38 toes with impending ulceration. Ten patients had neuropathic ulcers and six patients had neuro-ischaemic ulcers. Sixteen patients (42%) had macrovascular disease. Ten (26%) had proliferative rethinopathy, 7 (18%) macroalbuminuria and 18 (47%) microalbuminuria.
RESULTS: All surgical incisions healed uneventfully. Twenty-five (93%) of the toe ulcers healed in median 21 days (range 7-224 days). Three patients had recurrence of the ulcer. There were no infections in the incisions or toe amputations. No patients treated with preventive tenotomy experienced toe ulceration. No complications were recorded in neuro-ischaemic ulcers. During the follow up period of median 31 months (range 2-48 months) 33 other ulcers were recorded in 18 patients (47%). One of these developed a transfer ulceration under the adjacent metatarso-phalangeal joint and another had a late pressure ulcer on a neighbouring toe. The other 31 ulcers were not related to ulcers treated with tenotomy.
CONCLUSION: Tenotomy is a simple, safe and effective procedure for preventing and treating distal plantar neuropathic toe ulcers in claw toe or hammer toe deformities in people with diabetes with or without serious co-morbidity. The results suggest that tenotomy should be considered also in neuroischaemic ulcers.
Copyright © 2013 Tissue Viability Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Claw toe/hammer toe; Diabetes mellitus; Diabetic foot wounds; Foot surgery; Neuropathic ulcers; Tenotomy; Ulcer prevention

Mesh:

Year:  2013        PMID: 23809991     DOI: 10.1016/j.jtv.2013.04.001

Source DB:  PubMed          Journal:  J Tissue Viability        ISSN: 0965-206X            Impact factor:   2.932


  5 in total

1.  Australian guideline on prevention of foot ulceration: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Michelle R Kaminski; Jonathan Golledge; Joel W J Lasschuit; Karl-Heinz Schott; James Charles; Jane Cheney; Anita Raspovic
Journal:  J Foot Ankle Res       Date:  2022-07-06       Impact factor: 3.050

2.  Predictors of barefoot plantar pressure during walking in patients with diabetes, peripheral neuropathy and a history of ulceration.

Authors:  Ruth Barn; Roelof Waaijman; Frans Nollet; James Woodburn; Sicco A Bus
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

Review 3.  Effectiveness of percutaneous flexor tenotomies for the management and prevention of recurrence of diabetic toe ulcers: a systematic review.

Authors:  Jennifer E Scott; Gordon J Hendry; John Locke
Journal:  J Foot Ankle Res       Date:  2016-07-29       Impact factor: 2.303

4.  The effect of needle tenotomy on hammer, mallet and claw toe deformities in patients with diabetes, a retrospective study.

Authors:  Jonas Hedegaard Andersen; Anne Rasmussen; Marie Frimodt-Møller; Peter Rossing; Klaus Kirketerp-Møller; Susanne Engberg
Journal:  J Clin Transl Endocrinol       Date:  2019-10-12

5.  Safety and Efficacy of Several Versus Isolated Prophylactic Flexor Tenotomies in Diabetes Patients: A 1-Year Prospective Study.

Authors:  Mateo López-Moral; Raúl J Molines-Barroso; Yolanda García-Álvarez; Irene Sanz-Corbalán; Aroa Tardáguila-García; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.